Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611749 | 0.85 | ACHE (0.37) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL8965243 | 0.82 | ACHE (0.55) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL8965248 | 0.82 | ACHE (0.55) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL8948267 | 0.82 | ACHE (0.42) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL8948270 | 0.82 | ACHE (0.42) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL13604829 | 0.80 | ACHE (0.41) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL11473461 | 0.80 | CA2 (0.44) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL13611715 | 0.78 | POLB (0.35) | ACHEBACE1CA2CA1MAPK1 | |
| SCHEMBL7939874 | 0.78 | GPR84 (0.41) | CA2CA1TRPA1ACE2 | |
| SCHEMBL7939877 | 0.78 | GPR84 (0.41) | CA2CA1TRPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | CBR3, XDH, NQO2 | ACHE 484/4885BACE1 4260/4885CA2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.